Spanish industry turns on the pressure over debt, late payments
This article was originally published in Clinica
A decisive political commitment at the highest levels of Spain's national health service (SNS) is what is urgently needed to ensure that the debt and the delays in paying medical technology suppliers and service providers do not further damage the national health service.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.